| Identification | Back Directory | [Name]
ABBV-2222 (GLPG2222) | [CAS]
1918143-53-9 | [Synonyms]
ABBV2222
ABBV-2222
ABBV-2222 (GLPG2222)
GLPG-2222 (ABBV-2222) | [Molecular Formula]
C28H21F4NO7 | [MDL Number]
MFCD32899269 | [MOL File]
1918143-53-9.mol | [Molecular Weight]
559.46 |
| Chemical Properties | Back Directory | [Boiling point ]
701.1±60.0 °C(Predicted) | [density ]
1.56±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (89.37 mM; Need ultrasonic) | [form ]
Solid | [pka]
4.16±0.10(Predicted) | [color ]
White to off-white | [InChIKey]
QVDYQHXNAQHIKH-TZIWHRDSSA-N | [SMILES]
C(O)(=O)C1=CC=C([C@@H]2OC3=CC(OC(F)F)=CC=C3[C@H](NC(C3(C4=CC=C5OC(F)(F)OC5=C4)CC3)=O)C2)C=C1 |
| Hazard Information | Back Directory | [Uses]
Galicaftor (ABBV-2222; GLPG-2222) is a potent and orally active cystic fibrosis transmembrane conductance regulator (CFTR) corrector. Galicaftor can be used for cystic fibrosis research[1]. | [in vivo]
The rat pharmacokinetic tests are performed on Galicaftor (ABBV-2222; GLPG-2222; 1 mg/kg, i.v.; 1 mg/kg, p.o.) to illustrate its pharmacokinetic properties in rats. The T1/2 is 2.7 hours (i.v.). And for intragastric administration, the bioavailability (%F) is 74%[1]. | [References]
[1] Xueqing Wang, et al. Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator DOI:10.1021/acs.jmedchem.7b01339
[2] Ashvani K Singh, et al. Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222. J Pharmacol Exp Ther. 2020 Jan;372(1):107-118. DOI:10.1124/jpet.119.261800 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|